Abiomed, Inc. (ABMD)
| Market Cap | 12.16B |
| Revenue (ttm) | 812.94M |
| Net Income (ttm) | 200.47M |
| Shares Out | 45.20M |
| EPS (ttm) | 4.94 |
| PE Ratio | 54.36 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $268.56 |
| Previous Close | $262.71 |
| Change ($) | 5.85 |
| Change (%) | 2.23% |
| Day's Open | 266.28 |
| Day's Range | 261.27 - 272.92 |
| Day's Volume | 262,405 |
| 52-Week Range | 188.37 - 387.40 |
ABMD, CLMT, FLMN, GRUB, and IHG have been added to the Zacks Rank #5 (Strong Sell) List on May 4, 2021
Despite record revenue for its latest quarter, the medical device maker's shares sank 8% following its earnings release. But its next stage of growth is coming.
People will be getting back to their regular routines when it comes to medical and dental care.
ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.
Abiomed (ABMD) delivered earnings and revenue surprises of 12.73% and 4.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces record revenue of $241 million , up 17% year over year, with 26.0% operating margin.
DANVERS, Mass.--(BUSINESS WIRE)--Dr. Paula Johnson joins the Abiomed Board of Directors
Strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal fourth quarter as well.
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that i...
The best is yet to come for each of these companies.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, April 29, 2021 the Company will release financial results for the fourth quarter of fiscal 2021.
I've been waiting to buy these stocks at a better price. Now might just be the time.
Which healthcare company is a better play for the next decade?
CMD vs. ABMD: Which Stock Is the Better Value Option?
This medical device company has revenue growth, patents, and a bright outlook.
Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?
Investors searching for value opportunities may want to have a look at the three stocks listed below, as they represent equities in companies with high profitability and robust financial conditions. In ...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at upcoming investor conferences.
Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.
It's not a vaccine company, a drugmaker, or a diagnostics company.
The study proves that Abiomed's (ABMD) Impella 5.5 with SmartAssist delivers successful clinical and device outcomes.
Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% survival rate at expla...
The company released its latest quarterly report.
Abiomed, Inc.'s (ABMD) CEO Michael Minogue on Q3 2021 Results - Earnings Call Transcript
ABIOMED's (ABMD) international Impella revenues improve in Q3.
Abiomed (ABMD) delivered earnings and revenue surprises of 1.74% and 2.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Abiomed (NASDAQ:ABMD) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share rose 20.54% year over year to $1.35, which beat the estimate of $1.13.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q3 fiscal year 2021 record revenue of $232 million, up 5% year over year with 31% operating margin.
The strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal third quarter as well.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the company will release financial results for the third quarter of fiscal 2021 on January 28, 2021.
Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed's robust intellectual propert...
Abiomed's AAA financials, including a clean balance sheet and world-class margins can justify a premium in its valuation. Discounting Abiomed's future free cash flows, we derive the stock's intrinsic va...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at the 39th annual J.P. Morgan Healthcare conference.
Abiomed (ABMD) successfully treats first two patients in the world with the help of its Breethe OXY-1 System.
DANVERS, Mass.--(BUSINESS WIRE)--The first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, including a COVID-19 patient in respiratory failure.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP heart pump has com...
Biotech stocks simply can't match these reliable returns.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at the Stephens Annual Investment Conference 2020.
It depends on whether or not the company's decelerating revenue growth is a symptom of larger problems.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug Adminis...
Revenue bounces back, but growth is still lacking.
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q2 2021 Results - Earnings Call Transcript
ABIOMED's (ABMD) international Impella revenues improved in Q2.
Abiomed (ABMD) delivered earnings and revenue surprises of 16.09% and 4.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
About ABMD
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which... [Read more...]
| Industry Medical Devices | IPO Date Jul 29, 1987 |
| CEO Michael Minogue | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol ABMD |
Financial Performance
In 2019, Abiomed's revenue was $840.88 million, an increase of 9.29% compared to the previous year's $769.43 million. Earnings were $203.01 million, a decrease of -21.62%.
Analyst Forecasts
According to 9 analysts, the average rating for Abiomed stock is "Buy." The 12-month stock price forecast is 374.00, which is an increase of 39.26% from the latest price.